Have you evaluated the performance of Charles River Laboratories' (CRL) international operations during the quarter that concluded in December 2025? Considering the extensive worldwide presence of ...

Charles River Laboratories International, Inc. CRL reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.39, down 10.2% year over year. The figure surpassed the Zacks Consensus ...

Charles River Laboratories (CRL) reported $994.23 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 0.8%. EPS of $2.39 for the same period compares to $2 ...

Have you evaluated the performance of Charles River Laboratories' (CRL) international operations during the quarter that concluded in September 2025? Considering the extensive worldwide presence of ...

Event context and recent stock performance Without a specific headline event driving today’s move, Charles River Laboratories International (CRL) is drawing attention after a one-month return of about ...

Charles River Laboratories International, Inc. CRL reported second-quarter 2025 adjusted earnings per share (EPS) of $3.12, which rose 11.4% year over year. The figure surpassed the Zacks Consensus ...

CRL has consistently achieved ROE values above 12% since 2018. In addition, in the same period, its liabilities-to-assets ratio has exhibited a downward trend. The company has seen a considerable ...

Charles River Laboratories International Inc CRL reported Q1 sales of $1.03 billion, an increase of 12.6% Y/Y, beating the consensus of $986.35 million. The company reported adjusted EPS of $2.78, ...